A set of universal attachments for endotracheal (ET) tubes have been designed that allow for selective control of drug deposition in the lung. This novel invention provides clinicians with the ability to target aerosol delivery to either one side of the lung, or a specific lobe, which is beneficial for the treatment of regionally specific diseases. This device has great potential for use in hospitals as a method of applying personalized medicine to a variety of pulmonary diseases.
Regional targeting, which is a method of isolating aerosolized therapeutic delivery to only diseased areas of the lung through controlled drug release within the trachea, has yet to be implemented clinically. Although modifications to ET tubes have been proposed, none have demonstrated an ability to achieve lobe-specific deposition. Current ET tube designs are focused on ventilation control rather than drug delivery; thus, this newly developed technology would be the first proven method of targeting with drug release below the glottis.
· Increases efficiency of therapeutic delivery for lobe-specific diseases
· Easier to control drug release during intubation
· Aids in patient-specific targeting
· Decreases magnitude of off-target effects experienced by the patient
The specific design and devices of this invention are easily implemented attachments and adapters to existing ET tubes. Their use does not limit air flow but does allow the user to control the location of the drug release. Rather than a complete overhaul of the current system, this device is unique in that it is a simple modification of existing ET tube designs that can be easily integrated into existing clinical protocols and commercially-available devices. These modifications allow for the modulation of drug delivery profiles based on the location of diseased tissue.
The technology is patent pending. Further information on licensing opportunities is available on request.